Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
13.14
-0.07 (-0.49%)
Mar 31, 2025, 1:25 PM EDT - Market open
Dr. Reddy's Laboratories Employees
Dr. Reddy's Laboratories had 27,048 employees as of March 31, 2024. The number of employees increased by 1,185 or 4.58% compared to the previous year.
Employees
27,048
Change (1Y)
1,185
Growth (1Y)
4.58%
Revenue / Employee
$134,487
Profits / Employee
$23,189
Market Cap
11.15B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 27,048 | 1,185 | 4.58% |
| Mar 31, 2023 | 25,863 | 1,068 | 4.31% |
| Mar 31, 2022 | 24,795 | 2,056 | 9.04% |
| Mar 31, 2021 | 22,739 | 1,089 | 5.03% |
| Mar 31, 2020 | 21,650 | -316 | -1.44% |
| Mar 31, 2019 | 21,966 | -1,558 | -6.62% |
| Mar 31, 2018 | 23,524 | 853 | 3.76% |
| Mar 31, 2017 | 22,671 | 496 | 2.24% |
| Mar 31, 2016 | 22,175 | 1,802 | 8.85% |
| Mar 31, 2015 | 20,373 | 1,952 | 10.60% |
| Mar 31, 2014 | 18,421 | 1,804 | 10.86% |
| Mar 31, 2013 | 16,617 | 1,417 | 9.32% |
| Mar 31, 2012 | 15,200 | 277 | 1.86% |
| Mar 31, 2011 | 14,923 | 1,468 | 10.91% |
| Mar 31, 2010 | 13,455 | 2,227 | 19.83% |
| Mar 31, 2009 | 11,228 | 1,653 | 17.26% |
| Mar 31, 2008 | 9,575 | 555 | 6.15% |
| Mar 31, 2007 | 9,020 | 1,495 | 19.87% |
| Mar 31, 2006 | 7,525 | 1,390 | 22.66% |
| Mar 31, 2005 | 6,135 | -20 | -0.32% |
| Mar 31, 2004 | 6,155 | 303 | 5.18% |
| Mar 31, 2003 | 5,852 | 409 | 7.51% |
| Mar 31, 2002 | 5,443 | 314 | 6.12% |
| Mar 31, 2001 | 5,129 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RDY News
- 4 days ago - Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia - PRNewsWire
- 13 days ago - Alvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva® - Business Wire
- 18 days ago - Dr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion Bag - Business Wire
- 7 weeks ago - Dr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe - Business Wire
- 7 weeks ago - Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S. - PRNewsWire
- 2 months ago - Dr. Reddy's Lab: Near-Term Worries And Underappreciated Potential Could Lead To Huge Returns - Seeking Alpha
- 2 months ago - Dr. Reddy's Laboratories Limited (RDY) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Dr. Reddy's Q3 & 9MFY25 Financial Results - Business Wire